The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Researchers reveal a strategy that helps medulloblastoma, the most prevalent malignant brain tumor in children, spread and grow on the leptomeninges, the membranes surrounding the brain and spinal ...

Researchers at Baylor College of Medicine, Texas Children's Hospital, the Hospital for Sick Children in Toronto and ...

The way DNA folds inside the nucleus of brain cells may hold the key to understanding a devastating form of brain cancer called glioblastoma, suggests a new preclinical study. The findings offer a new ...

Overall, rates of new cancer diagnoses and cancer-related deaths have declined, according to the annual cancer statistics ...

Since Perakslis took over the varsity team from Graham in 2002, Abington has qualified for the state tournament 19 times. The ...

Overall cancer mortality rates decreased for men, women and children in the U.S. between 2018 and 2022, according to the National Cancer Institute’s “Annual Report to the Nation on the Status of ...

New research reveals CT scans may cause 5% of U.S. cancer cases annually. Learn the risks, who's most vulnerable, and how to ...

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises ...